Avalo to Present at ATS 2023 Respiratory Innovation Summit
May 15, 2023 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., May 15, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
May 10, 2023 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., May 10, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., Chief Executive Officer and Chairman of the Board,...
Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates
May 04, 2023 16:01 ET
|
Avalo Therapeutics
Topline data expected in the second quarter of 2023 from the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA)Disclosed cash of approximately $16.7 million as of March 31, 2023 ...
Avalo Reports 2022 Financial Results and Provides Business Updates
March 29, 2023 07:30 ET
|
Avalo Therapeutics
Completed enrollment of the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA); topline data expected in the second quarter of 2023Disclosed cash of approximately $13 million as of...
Avalo to Present at Oppenheimer's 33rd Annual Healthcare Conference
March 07, 2023 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., March 07, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) announced today that Garry A. Neil, M.D., President and Chief Executive Officer, will...
Avalo Therapeutics, Inc. Announces Pricing of $15 Million Public Offering of Common Stock and Warrants
February 02, 2023 21:54 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (Avalo) announced today the pricing of an underwritten public offering of 3,770,000 shares of...
Avalo Therapeutics, Inc. Announces Proposed Public Offering of Common Stock and Warrants
February 02, 2023 16:01 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”) announced today that it has commenced a proposed underwritten public offering of...
Avalo Announces it Has Completed Targeted Enrollment of 80 Patients in Phase 2 PEAK Trial of AVTX-002 in Non-Eosinophilic Asthma
January 17, 2023 07:00 ET
|
Avalo Therapeutics
Topline data expected in the second quarter of 2023 WAYNE, Pa. and ROCKVILLE, Md., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced that it completed...
Avalo Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 07, 2022 07:30 ET
|
Avalo Therapeutics
Topline data expected in the first half of 2023 from the Phase 2 PEAK Trial of AVTX-002 in non-eosinophilic asthma (NEA)Entered into agreement to sell future economic rights to previously out-licensed...
Avalo Sells Economic Rights to Previously Out-Licensed Assets for $5 Million
November 07, 2022 07:00 ET
|
Avalo Therapeutics
WAYNE, Pa. and ROCKVILLE, Md., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), today announced it entered into a purchase agreement to sell its economic rights to future...